Kevin T. Conroy Sells 125,402 Shares of EXACT Sciences Co. (EXAS) Stock
EXACT Sciences Co. (NASDAQ:EXAS) insider Kevin T. Conroy sold 125,402 shares of the company’s stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $52.79, for a total transaction of $6,619,971.58. Following the transaction, the insider now owns 955,454 shares in the company, valued at $50,438,416.66. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of EXACT Sciences Co. (NASDAQ:EXAS) traded down $5.27 during mid-day trading on Wednesday, hitting $47.68. The stock had a trading volume of 14,207,671 shares, compared to its average volume of 2,150,000. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01. The company has a market cap of $5,710.00, a PE ratio of -41.46 and a beta of 0.68. EXACT Sciences Co. has a one year low of $16.95 and a one year high of $63.60.
EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.07. The company had revenue of $72.60 million during the quarter, compared to analysts’ expectations of $65.03 million. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. EXACT Sciences’s revenue was up 158.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.36) EPS. analysts anticipate that EXACT Sciences Co. will post -1.09 EPS for the current year.
EXAS has been the topic of a number of research reports. Canaccord Genuity upgraded shares of EXACT Sciences to a “buy” rating and set a $60.00 target price on the stock in a research report on Tuesday, October 31st. Leerink Swann restated an “outperform” rating and set a $67.00 target price (up from $63.00) on shares of EXACT Sciences in a research report on Monday, November 13th. Benchmark set a $65.00 target price on shares of EXACT Sciences and gave the company a “buy” rating in a research report on Wednesday. Robert W. Baird upped their target price on shares of EXACT Sciences from $49.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 31st. Finally, Jefferies Group upped their target price on shares of EXACT Sciences to $60.00 and gave the company a “buy” rating in a research report on Tuesday, October 31st. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. EXACT Sciences currently has an average rating of “Buy” and an average target price of $51.64.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/17/kevin-t-conroy-sells-125402-shares-of-exact-sciences-co-exas-stock.html.
About EXACT Sciences
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.